Is fluorescein-guided technique able to help in resection of high-grade gliomas?
2014; American Association of Neurological Surgeons; Volume: 36; Issue: 2 Linguagem: Inglês
10.3171/2013.11.focus13487
ISSN1092-0684
AutoresFrancesco Acerbi, Morgan Broggi, Marica Eoli, Elena Anghileri, Claudio Cavallo, Carlo Boffano, Roberto Cordella, Lucia Cuppini, Bianca Pollo, Marco Schiariti, Sergio Visintini, Chiara Orsi, Emanuele La Corte, Giovanni Broggi, Paolo Ferroli,
Tópico(s)Nanoplatforms for cancer theranostics
ResumoObject Fluorescein, a dye that is widely used as a fluorescent tracer, accumulates in cerebral areas where the blood-brain barrier is damaged. This quality makes it an ideal dye for the intraoperative visualization of high-grade gliomas (HGGs). The authors report their experience with a new fluorescein-guided technique for the resection of HGGs using a dedicated filter on the surgical microscope. Methods The authors initiated a prospective Phase II trial (FLUOGLIO) in September 2011 with the objective of evaluating the safety of fluorescein-guided surgery for HGGs and obtaining preliminary evidence regarding its efficacy for this purpose. To be eligible for participation in the study, a patient had to have suspected HGG amenable to complete resection of the contrast-enhancing area. The present report is based on the analysis of the short- and long-term results in 20 consecutive patients with HGGs (age range 45–74 years), enrolled in the study since September 2011. In all cases fluorescein (5–10 mg/kg) was injected intravenously after intubation. Tumor resection was performed with microsurgical technique and fluorescence visualization by means of BLUE 400 or YELLOW 560 filters on a Pentero microscope. Results The median preoperative tumor volume was 30.3 cm 3 (range 2.4–87.8 cm 3 ). There were no adverse reactions related to fluorescein administration. Complete removal of contrast-enhanced tumor was achieved in 80% of the patients. The median duration of follow-up was 10 months. The 6-months progression-free survival rate was 71.4% and the median survival was 11 months. Conclusions Analysis of these 20 cases suggested that fluorescein-guided technique with a dedicated filter on the surgical microscope is safe and allows a high rate of complete resection of contrast-enhanced tumor as determined on early postoperative MRI. Clinical trial registration no.: 2011-002527-18 (EudraCT).
Referência(s)